[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"extracorporeal-membrane-oxygenation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:extracorporeal-membrane-oxygenation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,52,92,131,156,178,206,229,251,272,297,325,350,380,400,426,457,481,508],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100492965","phase-1-individualized-or-conventional-transfusion-strategies-during-peripheral-va-ecmo-100492965",false,"NCT05699005","Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO","Comparison of an Individualized Transfusion Strategy to a Conventional Strategy in Patients Undergoing Peripheral Veno-arterial ECMO for Refractory Cardiogenic Shock: a Randomized Controlled Trial - ICONE","ICONE","Inclusion Criteria:\n\n* Age of 18 and older,\n* supported by peripheral VA-ECMO\n* for cardiogenic shock\n* Life expentency \\>90 days\n* Central venous line available ScVO2 measurement\n\nExclusion Criteria:\n\n* Pregnancy,\n* Lack of health insurance,\n* Opposition to blood transfusion,\n* Known congenital hemoglobin disease or disorder,\n* Metabolic alcaloosis with pH\\>7.8,\n* eCPR,\n* Legally incapacitated adults","ALL","18 Years",{"count":20,"type":21},236,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This multicenter randomized controlled trial compare two transfusion strategies of red blood cells transfusion in patients supported by veno-arterial extracorporeal membrane oxygenation for refractory cardiogenic shock.\n\nAn individualized transfusion strategy based on ScVO2 level, is compared to a conventionnal strategy based on predefined hemoglobin threshold. The primary endpoint is the consumption of packed red blod cells, secondary endpoints are subgroup analysis, mortality, morbidity, and cost-effectiveness",[27,28,29,30,31],"Cardiogenic Shock","Extracorporeal Membrane Oxygenation","Transfusion Related Complication","Anemia","Oxygen Delivery",[33,34,35,36,37,38],"ECMO","ECLS","Refractory cardiogenic shock","Transfusion","ScVO2","Outcome","RECRUITING","2026-06-30",{"date":42,"type":43},"2026-07-02","ACTUAL",{"date":45,"type":43},"2023-09-18",{"date":47,"type":21},"2028-12-18",{"name":49,"class":50},"University Hospital, Lille","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":51},"100644735","personalized-ventilator-settings-for-patients-on-ecmo-100644735","NCT07673250","Personalized Ventilator Settings for Patients on ECMO","Personalized Ventilator Settings for Patients on ECMO (PEEPECMO)","PEEPECMO","1. History of Lung or Cardiac Transplantation, or definite bridge to transplantation\n2. Patient is not committed to full support\n3. Treating clinician refusal, or unwillingness to commit to controlled therapeutics (Esophageal Pressure Guided Positive End-Expiratory Pressure and neuromuscular blockade)\n4. Inability to get informed consent from the patient or legally authorized representative (LAR)\n5. Patients with contraindications to esophageal balloon placement or inability to successfully place an esophageal balloon will have personalized PEEP determined by electrical impedance tomography.\n\n   a. Contraindications include recently treated or bleeding varices, esophageal stricture, hematemesis, esophageal trauma, recent esophageal surgery or other contraindication for nasogastric tube placement, or severe coagulopathy.\n6. Severe barotrauma that requires lower mean airway pressure (i.e., PEEP) per the treating physician.\n7. Patients who are pregnant or prisoners.\n8. Has been on V-V ECMO \\> 72 hours.",{"count":61,"type":21},62,[63],"NA","While mechanical ventilation can be used to sustain life in those with lung injury, it, can further worsen lung injury or prevent lung healing resulting in high morbidity and mortality as seen in Acute Respiratory Distress Syndrome (ARDS).\n\nUsing extracorporeal membrane oxygenation (ECMO), the highest level of life support also known as the heart-lung machine, investigators may minimize injury from mechanical ventilation to allow the lungs to heal; however, the optimal ventilator strategies while on ECMO are unknown. This study will evaluate personalized ventilator strategy compared to standard of care ventilation.",[66,28,67,68,69],"Acute Respiratory Distress Syndrome (ARDS)","Respiratory Failure Patients Treated With ECMO","Respiratory Failure, ICU","Ventilator Induced Lung Injury",[71,72,73,33,74,75,76,77,78,79,80,81],"Respiratory failure","ARDS","Acute Respiratory Distress Syndrome","Pneumonia","Lung injury","Influenza","COVID","Viruses","Personalized ventilator settings","Positive end expiratory pressure","PEEP","NOT_YET_RECRUITING","2026-06-22",{"date":85,"type":43},"2026-06-29",{"date":87,"type":21},"2026-09-01",{"date":89,"type":21},"2031-06-30",{"name":91,"class":50},"University of California, San Diego",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":111,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":129,"locationsCount":51},"100640195","feasibility-of-protocolised-analgosedation-in-ecmo-100640195","NCT07580781","Feasibility of Protocolised Analgosedation in ECMO","Feasibility of a Cluster Randomised Control Trial Evaluating a Co-designed Analgosedation Protocol in Extracorporeal Membrane Oxygenation (ECMO) Patients","ECMO-SED","Inclusion Criteria:\n\n* Aged 18 years and older\n* Receiving IV continuous infusions of analgosedation medication\n* Receiving ECMO treatment\n\nExclusion Criteria:\n\n* There will be no exclusion criteria as analgosedation management is routine for all adult ECMO patients.",{"count":101,"type":21},60,[63],"Sedation (painkillers and sedative drugs) treats pain, reduces suffering, and helps patients in the intensive care unit (ICU) receiving extracorporeal membrane oxygenation (ECMO) remain comfortable. ECMO is a life support machine that provides oxygen and removes waste gases (carbon dioxide) in very sick patients with severe heart or lung failure. About 300-400 patients per year receive ECMO in the UK. These patients are younger and generally more healthy compared to other critically ill patients. However patients that survive ECMO have long-term health problems. These include anxiety, memory problems, withdrawal from medicines, and mobility issues. These problems issues could all be related to the type and amount of sedation given.\n\nA sedation protocol is a way of guiding healthcare professionals how much sedation is given to patients in ICU. Too much sedation can cause confusion, hallucinations, excessive sleepiness, and longer time in hospital. Too little sedation can cause pain, distress, and also a longer time in hospital. Using a sedation protocol in non-ECMO patients has been shown to reduce these complications.\n\nHowever, there are no protocols for giving sedation to ECMO patients in research papers. Investigators know healthcare staff find it difficult to manage sedation, and higher amounts of sedation is given to ECMO patients.\n\nAims:\n\nTo see whether it is possible to run a trial that compares using a sedation protocol against usual care.\n\nDesign\u002Fmethods:\n\nThirty to 60 ECMO patients will be chosen and will be put into one of two groups. One group will receive usual care, and the other will receive care using the sedation protocol. The investigators will collect information from both groups to find out if the study design works and how many patients agree to take part.\n\nPatient and public involvement\u002Fengagement:\n\nThe investigators received feedback from patients and family member participants which helped to design this proposal, the lay summary and what to measure in a trial. They will advise how the investigators should review study findings, and support sharing of results to the public.\n\nImpact\u002Fdissemination:\n\nThe investigators will share findings through social media, patient charities, research papers and conferences.",[105,106,107,28,108,27,109,110],"Intensive Care (ICU)","Respiratory Distress Syndrome (RDS)","Sedation and Analgesia","Sedation for Mechanical Ventilation","Opioid Analgesia","Analgesia",[112,113,114,115,116,117,33,118,119,120,121,122],"extracorporeal membrane oxygenation","sedation","opioid","sedative","analgosedation","mechanical ventilation","ICU","Intensive Care Unit","Critical Care","sedation protocol","analgesia","2026-05-05",{"date":125,"type":43},"2026-05-12",{"date":87,"type":21},{"date":128,"type":21},"2027-08-31",{"name":130,"class":50},"Guy's and St Thomas' NHS Foundation Trust",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":138,"maxAge":18,"enrollmentInfo":139,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":51},"100416957","ecmo-treatment-of-children-in-china-in-the-past-10-years-100416957","NCT04709432","ECMO Treatment of Children in China in the Past 10 Years","Extracorporeal Membrane Oxygenation (ECMO) Treatment of Children in Mainland China in the Past 10 Years","Inclusion Criteria:\n\n* age of 1d to 18 years old;\n* children supported by ECMO in mainland China in the past 10 years\n\nExclusion Criteria:\n\n* none","1 Day",{"count":140,"type":21},500,"OBSERVATIONAL","It is a cross-sectional study to summarize the extracorporeal membrane oxygenation （ECMO）treatment in children in China.",[28,144],"Child, Only",[146],"Extracorporeal membrane oxygenation; children; complication","2026-03-13",{"date":149,"type":43},"2026-03-16",{"date":151,"type":43},"2021-01-11",{"date":153,"type":21},"2026-12-31",{"name":155,"class":50},"Children's Hospital of Fudan University",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":162,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":51},"100377765","predictors-for-survival-and-good-neurological-outcome-in-e-cpr-and-non-cpr-treated-patients-100377765","NCT04198792","Predictors for Survival and Good Neurological Outcome in E-CPR and Non CPR Treated Patients","Inclusion Criteria:\n\n* ECMO-treated patients.\n\nExclusion Criteria:\n\n* None","16 Years",{"count":164,"type":21},700,"In ECPR, where CPR times often range from 30 to 120 minutes, only patients with good circulation during CPR survive, while non-survivors commonly suffer from anoxic brain injury. The selection process during CPR is challenging causing a general survival rate of just 2 out of 10, and the urgent need for better selection criteria has been emphasized. It it crucial to keep cardiac arrest times as short as possible, pre primed-ECMO can facilitate this.\n\nThe ECMO treatment and the long CPR times of ECPR can also affect the measurements of the neurologic prognostication guidelines after cardiac arrest, making its validity uncertain in this specific cohort. Further, the long-term neuropsychological follow-up is limited to a few patients, making it uncertain if ECPR gives the survivors good long-term life satisfaction or just a prolonged life.\n\nOur overall aim is to optimize and improve the care pathway for ECPR patients by refining patient selection, assessing pre-primed ECMO, validating neurological prognostication guidelines, and understanding long-term outcomes and challenges faced by survivors.\n\nSpecific Aim 1: Evaluating predictors for good neurological outcomes in ECPR and to develop and validate (internally and externally) an evidence-based selection tool for ECPR.\n\nSpecific aim 2: To assess the sterility and function of pre-primed ECMO.\n\nSpecific aim 3: To evaluate the applicability of current guidelines for neurological prognostication after cardiac arrest in ECPR patients, and to assess the predictive value of individual and combined neurological tests in this specific patient population.\n\nSpecific aim 4: To determine the long-term neuropsychological outcomes, identify the problems survivors experience in daily life, and assess life satisfaction - by comprehensive follow-up visits with validated questionnaires and neuropsychology testing up to 12 years after the ECMO-treated cardiac arrest.",[167,28,168],"Cardiac Arrest","Hypoxia-Ischemia, Brain","2026-01-14",{"date":171,"type":43},"2026-01-20",{"date":173,"type":43},"2010-01-01",{"date":175,"type":21},"2030-01-01",{"name":177,"class":50},"Sahlgrenska University Hospital",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":185,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":205},"100469123","ards-in-children-and-ecmo-initiation-strategies-impact-on-neurodevelopment-ascend-100469123","NCT05388708","ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)","ASCEND","Inclusion Criteria:\n\n* Time between intubation and ECMO cannulation is less than 240 hours (10 days)\n* ECMO support type is respiratory (VV or VA cannulation)\n* Chest radiograph with bilateral lung disease\n* Moderate or severe pediatric ARDS as measured by oxygenation index or oxygen saturation index after intubation and prior to ECMO cannulation:\n\nOne OI ≥ 16 or Two OIs ≥ 12 and ≤ 16 at least four hours apart or Two OSIs ≥ 10 at least four hours apart or One OI ≥ 12 and ≤ 16 and One OSI ≥ 10 at least four hours apart\n\nExclusion Criteria:\n\n* Previously enrolled in PROSpect\n* Perinatal related lung disease\n* Congenital diaphragmatic hernia or congenital\u002Facquired diaphragm paralysis\n* Respiratory failure caused by cardiac failure or fluid overload\n* Cyanotic congenital heart disease\n* Cardiomyopathy\n* Primary pulmonary hypertension (PAH)\n* Unilateral lung disease\n* Intubated for status asthmaticus\n* Obstructive airway disease\n* Bronchiolitis obliterans\n* Post hematopoietic stem cell transplant\n* Post lung transplant\n* Home ventilator dependent\n* Neuromuscular respiratory failure\n* Head trauma: (managed with hyperventilation)\n* Intracranial bleeding\n* Unstable spine, femur or pelvic fractures\n* Acute abdominal process\u002Fopen abdomen\n* Family\u002Fmedical team have decided to not provide full support\n* Enrolled in interventional clinical trial: not approved for co-enrollment; does not include cancer protocols.\n* Known pregnancy","14 Days","20 Years",{"count":188,"type":21},550,"ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives.\n\nThe first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatric intensive care unit. The second objective is to compare short and long-term patient outcomes in two groups of children: one group managed with a mechanical ventilation protocol that reserves the use of extracorporeal membrane oxygenation (ECMO) until protocol failure to another group supported on ECMO per usual care.",[73,28],[72,73,28,33,192,34,193,194,195],"Extracorporeal Life Support","Pediatric","Quality of Life","Functional Status","2025-12-22",{"date":198,"type":43},"2025-12-24",{"date":200,"type":43},"2021-02-04",{"date":202,"type":21},"2027-09-30",{"name":204,"class":50},"University of Michigan",99,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":213,"enrollmentInfo":214,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":51},"100520872","effect-of-transpulmonary-mp-on-prognosis-of-patients-with-severe-ards-treated-with-vv-ecmo-100520872","NCT06062212","Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO","Effect of Transpulmonary Mechanical Power on the Prognosis of Patients With Severe Acute Respiratory Distress Syndrome Treated With Venovenous Extracorporeal Membrane Oxygenation","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of Berlin's definition for ARDS;\n2. Receiving VV-ECMO support.\n\nExclusion Criteria:\n\n1. Patients had been on high pressure (Ppeak \\>35 cm H2O) and a high fraction of inspired oxygen (FiO2\\>0.8) ventilation for \\>7 days;\n2. Patients had a contraindication to heparinization;\n3. Patients had an irreversible neurological injury;\n4. Patients had severe chronic lung disease with life expectancy \\\u003C6 months.","75 Years",{"count":215,"type":21},100,"Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a salvage treatment for severe acute respiratory distress syndrome (ARDS). With the large-scale implementation of VV-ECMO in critical care medicine departments in China, significant progress has been made in treating severe ARDS. However, the patient mortality rate remains high. The pathophysiological essence of ARDS is an imbalance between the body's oxygen supply and demand, causing tissue and cell hypoxia, organ dysfunction, and even death. The VV-ECMO treatment process still requires mechanical ventilation assistance. However, inappropriate mechanical ventilation settings can lead to ventilator-related lung injury (VILI). In recent years, mechanical power has gradually attracted everyone's attention and is considered the cause of VILI. The transpulmonary mechanical power is more accurate to the energy directly performed to the lung tissue. Transpulmonary mechanical energy has a specific value in judging the prognosis of mechanically ventilated patients, but its clinical significance in treating patients with VV-ECMO is unclear. This study aimed to explore the value of transpulmonary mechanical power in predicting the prognosis of patients with severe ARDS patients treated with VV-ECMO.",[73,28,218,219],"Mechanical Power","Transpulmonary Mechanical Power","2025-07-02",{"date":222,"type":43},"2025-07-03",{"date":224,"type":43},"2023-10-01",{"date":226,"type":21},"2025-12-31",{"name":228,"class":50},"Beijing Chao Yang Hospital",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":248,"locationsCount":250},"100483381","phase-1-hydrogens-feasibility-and-safety-as-a-therapy-in-ecpr-100483381","NCT05574296","Hydrogen's Feasibility and Safety as a Therapy in ECPR","Hydrogen's Feasibility and Safety as a Therapy in Extracorporeal Cardiopulmonary Resuscitation","HydrogenFAST","INCLUSION CRITERIA\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Patients admitted to a cardiac intensive care unit at a participating site with cardiac comorbidity, including congenital heart disease, myocarditis, cardiac arrhythmia, or rejection of a transplanted heart.\n2. Patients are anticipated to be between birth to 18 years of age, although occasionally a patient over the age of 18 may be enrolled.\n3. Patient experiencing a refractory cardiac arrest \\>5 minutes and receiving ongoing CPR in the ICU, cardiac catheterization lab, or cardiac operating room.\n4. The decision made by the clinical team to resuscitate from ongoing, refractory cardiac arrest using ECPR due to a lack of other available options.\n\nEXCLUSION CRITERIA\n\nMeeting any of the following criterion renders the patient ineligible for the trial:\n\n1. Enrollment in the opt-out program.\n2. Patients known to be pregnant.\n3. Patients who are prisoners.\n4. Prior ECPR episode during admission (whether or not they were enrolled in the trial).\n5. Enrollment does not occur within 6 hours of the decision to resuscitate using ECPR.\n\nNote that ECMO cannulation without preceding CPR does not qualify as ECPR and such patients will not be included.",{"count":238,"type":21},53,[24],"The purpose of this project is to test the feasibility and safety of inhaled hydrogen gas (H2) administration as a rescue therapy during cardiac arrest requiring extracorporeal cardiopulmonary resuscitation (ECPR, i.e. mechanical circulatory support). Under exemption from informed consent, patients undergoing refractory cardiac arrest in the cardiac ICU at a participating center will be randomized to standard therapy with or without the administration of 2% hydrogen in gases administered via the ventilator and ECMO membrane for 72 hours.",[167,28,242],"Reperfusion Injury","2025-07-01",{"date":222,"type":43},{"date":246,"type":43},"2024-03-04",{"date":128,"type":21},{"name":249,"class":50},"Boston Children's Hospital",4,{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":271,"locationsCount":51},"100527821","evaluation-of-membrane-lung-function-in-high-altitude-regions-100527821","NCT06152744","Evaluation of Membrane Lung Function in High-altitude Regions","Evaluation of Membrane Lung Function for Patients Receiving Venovenous Extracorporeal Membrane Oxygenation in High-altitude Regions","Inclusion Criteria:\n\n* Receiving ECMO support\n\nExclusion Criteria:\n\n* Unable to obtain post-membrane blood gas\n* Pregnancy\n* Patients cannot receive anticoagulation\n* Refusal to participate in the trial","70 Years",{"count":260,"type":21},40,"Over the last 20 years, extracorporeal membrane oxygenation (ECMO) has been used to support adult patients with respiratory or cardiac failure who are unlikely to survive conventional treatment methods. ECMO circuit, pump, and oxygenator technology improvements permit safer perfusion for extended periods. The prolonged use of an ECMO circuit increases the risk of membrane lung (ML) dysfunction. The ML is responsible for taking in oxygen and removing carbon dioxide. The non-biologic surface of the ML triggers inflammatory and coagulation pathways, resulting in the formation of blood clots, breakdown of fibrin, and activation of white blood cells, which ultimately leads to ML dysfunction. Coagulation and fibrinolysis activation can cause systemic coagulopathy or hemolysis, and the deposition of blood clots can block blood flow. Moreover, the accumulation of moisture in the gas phase and the buildup of protein and cellular debris in the blood phase may contribute to shunt and dead-space physiology, respectively, impairing the exchange of gases. These three categories-hematologic abnormalities, mechanical obstruction, and inadequate gas exchange-account for most ML exchanges. Worsening oxygenation during ECMO should prompt quantification of oxygen transfer. ML exchange is indicated when the ML can no longer meet the patient's oxygen demand. The partial pressure of Post-ML arterial oxygen less than 200 mmHg is the most important consideration in this decision. In some high-altitude regions of China, ECMO treatment is also routinely conducted. The experiences above are derived from low-altitude areas, and whether they apply in high-altitude regions is still being determined. This study aimed to explore the significantly lower membrane lung oxygen uptake in high-altitude regions compared to low-altitude areas.",[28,263,264],"Membrane Lung Function","High Altitude","2025-06-13",{"date":267,"type":43},"2025-06-17",{"date":269,"type":43},"2023-12-05",{"date":226,"type":21},{"name":228,"class":50},{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":282,"briefSummary":283,"conditions":284,"keywords":286,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":296},"100559133","restrictive-versus-liberal-thresholds-for-rbc-transfusion-in-ecmo-100559133","NCT06560164","Restrictive Versus Liberal Thresholds for RBC Transfusion in ECMO","Restrictive Versus Liberal Thresholds for Red Blood Cell Transfusion in ExtraCorporeal Membrane Oxygenation - the TREC Study","TREC","Inclusion Criteria:\n\n* Patient is aged 18 years or older;\n* Is receiving ECMO;\n* (Deferred) informed consent.\n\nExclusion Criteria:\n\n* Not expected to survive for 24 hours when assessed;\n* Inability to receive blood products;\n* (Known) decline to blood transfusions (e.g., Jehovah's Witnesses);\n* Extracorporeal carbon dioxide removal (ECCO2R) using low blood flow devices or pumpless devices (i.e., MINILUNG ®, PrismaLung+);\n* Received ECMO over 48h before screening for eligibility.",{"count":281,"type":21},526,[63],"Rationale: In patients supported with extracorporeal membrane oxygenation (ECMO), transfusion of red blood cells (RBC) is very common. This is possibly due to the application of liberal thresholds and the lack of evidence-based guidelines. Although RBC transfusion can be lifesaving, it is also a risk-bearing intervention with substantial risk for morbidity and mortality in this critically ill population. Also, with increasing scarcity, RBC transfusions are becoming more expensive. Furthermore, in the past decades it has been shown in several critically ill patient populations - not on ECMO - that maintaining a restrictive hemoglobin (Hb) threshold for RBC transfusion is non-inferior, including in cardiothoracic surgery, acute myocardial infarction and septic shock. Therefore, the investigators hypothesize that a restrictive transfusion threshold for RBC is safe to apply in patients on ECMO in comparison with a liberal transfusion threshold.\n\nObjective: The primary objective of this trial is to study in a prospective randomized comparison whether a restrictive RBC transfusions strategy is non-inferior compared to a liberal strategy in patients on ECMO with respect to 90-day mortality.\n\nStudy design: Prospective multi-center randomized controlled non-inferiority trial.\n\nStudy population: Patients, 18 years or older, receiving ECMO.\n\nIntervention: Restrictive RBC transfusion threshold: in case the Hb transfusion trigger of 7.0 g\u002FdL (4.3 mmol\u002FL) is reached, 1 RBC unit at a time will be transfused. The aimed Hb target range of the restrictive\u002Fintervention group will be 7.1 - 9.0 g\u002FdL (4.3 - 5.6 mmol\u002FL). Liberal RBC transfusion threshold: in case the Hb transfusion trigger of 9.0 g\u002FdL (5.6 mmol\u002FL) is reached, 1 RBC unit at a time will be transfused. Target range of the liberal group is defined as Hb 9.1 - 11.0 g\u002FdL\n\nMain study parameters\u002Fendpoints: The primary outcome parameter is 90-day all-cause mortality.\n\nSecondary outcomes include: 1) proportion of patients on ECMO exposed to allogeneic RBC transfusion; 2) RBC volume infused per patient during ECMO; 3) reasons for RBC transfusion other than Hb triggers; 4) transfusion reactions; 5) time on ECMO; 6) length of hospital- and ICU-stay; 7) in-ICU morbidity; 8) quality of life (QoL), iMTA Medical Consumption Questionnaire (iMCQ) and Productivity Cost Questionnaire (iPCQ) at 3, 6, 9, and 12 months; 9) costs related to a) transfusion, b) hospital admission and c) transfusion-related sequelae.",[36,285,28,30,33],"Red Blood Cell",[36,285,28,30,33],"2025-04-04",{"date":289,"type":43},"2025-04-08",{"date":291,"type":43},"2024-11-26",{"date":293,"type":21},"2029-10-01",{"name":295,"class":50},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",12,{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":312,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":324},"100447442","efficacy-and-safety-of-synchronized-cardiac-support-in-cardiogenic-shock-patients-100447442","NCT05106491","Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients","Evaluating the Efficacy and Safety of the Synchronized Cardiac Support Treatment with the Icor Kit in Patients with Cardiogenic Shock - a Pivotal Study (Pulse SE)","PulseSE","Inclusion Criteria:\n\n1. Informed consent signed and dated by study patient\u002Flegal representative and investigator\u002Fauthorised physician\n2. Minimum age of 18 years\n3. Patients in cardiogenic shock\n4. Cardiogenic shock is defined as:\n\n   1. Systolic blood pressure \\\u003C 90 mmHg for at least 30 min\n   2. Inotropes and\u002For vasopressors are needed to maintain systolic blood pressure \\> 90 mmHg\n   3. Clinical signs of heart insufficiency with pulmonary congestion\n5. Signs of end organ hypoperfusion with at least one of the following criteria:\n\n   1. Cold, damp skin or extremities\n   2. Oliguria (≤ 30 mL\u002Fh)\n6. Serum lactate \\> 3.0 mmol\u002FL\n\nExclusion Criteria:\n\n1. In case of female patients: pregnancy or lactation period\n2. Participation in an interventional clinical study during the preceding 30 days\n3. Previous participation in the same study\n4. Age \\> 85 years\n5. Cardiac arrest out of hospital with return of spontaneous circulation (ROSC) \\> 30 min\n6. No flow time \\> 5 min\n7. Mechanical causes for cardiogenic shock (ventricular septal defect of papillary muscle rupture)\n8. Non-cardiogenic causes of shock (bradycardia, sepsis, hypovolemia, etc.)\n9. Fever (Body temperature \\> 38.0 °C) or other evidence of sepsis\n10. Onset of cardiogenic shock \\> 6 h before enrolment\n11. Lactate \\> 16 mmol\u002FL\n12. Severe peripheral arterial occlusive disease precluding insertion of femoral arterial or venous catheters\n13. Contra-indications for anticoagulation\n14. Contra-indication for VA ECMO, e.g. unrecoverable heart and not a candidate for transplant or VAD","85 Years",{"count":307,"type":21},21,[63],"The study aims to investigate the safety and efficacy of the Synchronized Cardiac Support treatment wit the icor kit and the Xenios console with modified sensor box ECG and Software Version 3.2.4",[27,28,34,311],"VA ECMO",[27,28,313,34,311],"Synchronized Cardiac Support","2025-03-13",{"date":316,"type":43},"2025-03-14",{"date":318,"type":21},"2025-09",{"date":320,"type":21},"2026-09",{"name":322,"class":323},"Xenios AG","INDUSTRY",2,{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":333,"targetDuration":335,"studyType":141,"phases":4,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":51},"100582391","effect-of-reduced-vasopressors-on-mortality-in-ecmo-supported-cardiogenic-shock-patients-100582391","NCT06862700","Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients","Association Between Vasopressor Exposure Levels and 30-Day Mortality in Patients Receiving ECMO Support for Cardiogenic Shock: A Prospective Multicenter Cohort Study","VREM-CS","Inclusion Criteria:\n\n* Adults (≥18 years) with cardiogenic shock requiring VA-ECMO support.\n* First-time ECMO initiation.\n* Venoarterial ECMO (VA-ECMO) as the initial mode.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* Severe pulmonary hypertension.\n* Vasopressor use for non-shock indications (e.g., bleeding, post-cardiopulmonary bypass vasoplegia).\n* Severe missing data.",{"count":334,"type":21},534,"30 Days","The goal of this observational study is to learn about the association between vasopressor exposure levels and outcomes in adults with cardiogenic shock receiving VA-ECMO. The main question it aims to answer is:\n\nDoes reduced exposure to vasopressors lower the 30-day mortality in patients with cardiogenic shock when receiving ECMO support? Participants who are receiving ECMO support for cardiogenic shock as part of their regular medical care will have their data collected, including information about their vasopressor use and mortality outcomes, over the course of the study.",[27,28,338,339,120,340],"Vasopressors","Hemodynamic Management","Heart Failure","2025-03-04",{"date":343,"type":43},"2025-03-06",{"date":345,"type":43},"2025-02-26",{"date":347,"type":21},"2028-01-01",{"name":349,"class":50},"Xiaotong Hou",{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":258,"enrollmentInfo":358,"targetDuration":4,"studyType":22,"phases":360,"briefSummary":361,"conditions":362,"keywords":367,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":4},"100577980","the-osiris-ecpr-trial-100577980","NCT06805344","The OSIRIS ECPR Trial","Out-of-hospital Refractory Cardiac Arrest Treated with Extracorporeal Cardiopulmonary Resuscitation","OSIRIS","Inclusion Criteria:\n\n1. Age ≥18 and ≤ 70 years presumed or known\n2. Witnessed OHCA\n3. Bystander CPR provided\n4. Presumed cardiac or unknown cause\n5. An initial documented shockable rhythm of VF (ventricular fibrillation) or pulseless VT (ventricular tachycardia)\n6. Minimum of ≥ 10 min of ACLS without ROSC or at least ≥ 3 defibrillations in ongoing VF\u002Fpulseless VT\n7. Body morphology able to accommodate a mechanical chest compression device\n8. ECPR team and intensive care unit (ICU) capacity in the receiving center available\n9. Estimated transfer time from the scene to the hospital ≤ 30 minutes or to the scene ≤ 30 minutes\n10. Eligible for intensive care without restrictions or limitations\n\nExclusion Criteria:\n\n1. ACLS ≥ 30 minutes before randomization\n2. Known limitations in care or a Do Not Attempt to Resuscitate (DNAR) order\n3. Known severe disease making 90-day survival unlikely\n4. Known bleeding diathesis or acute or recent intracranial bleeding\n5. Known, obvious or suspected pregnancy\n6. Known pre-arrest severe cognitive dysfunction (mRS ≥ 4)\n7. Known hypothermia as a cause of cardiac arrest",{"count":359,"type":21},686,[63],"The OSIRIS trial is an investigator-initiated, multicenter, multinational, open-label, randomized controlled trial with a 2:1 concealed allocation of refractory out-of-hospital cardiac arrest (OHCA) patients to the extracorporeal cardiopulmonary resuscitation (ECPR) based approach versus the conventional cardiopulmonary resuscitation (CCPR) approach.",[167,363,364,365,366,28],"Ventricular Fibrillation","Out-Of-Hospital Cardiac Arrest","Sudden Cardiac Arrest","Extracorporeal Cardiopulmonary Resuscitation",[368,369,112,370],"cardiac arrest","extracorporeal cardiopulmonary resuscitation","out-of-hospital cardiac arrest","2025-01-30",{"date":373,"type":43},"2025-02-03",{"date":375,"type":21},"2025-02",{"date":377,"type":21},"2030-06",{"name":379,"class":50},"General University Hospital, Prague",{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":51},"100420446","reduction-of-blood-recirculation-in-veno-venous-ecmo-100420446","NCT04754854","Reduction of Blood Recirculation in Veno-Venous ECMO","Reduction of Blood Recirculation in Veno-Venous ECMO Through Ultrasound Dilution Measurements (ECMO Circulation Study)","Patients aged 18 years or older requiring veno-venous ECMO for treatment of refractory hypoxemia in ARDS.",{"count":388,"type":21},136,"Blood which recirculates through the circuit of a veno-venous Extracorporeal Membrane Oxygenation (V-V ECMO) does not contribute to the systemic oxygenation of a patient on V-V ECMO and is called the recirculation fraction (Rf). Theoretically, the optimization of ECMO blood flow is possible using Rf measurements.\n\nA prospective, observational study will be performed measuring the Rf of total ECMO blood flow in patients with acute respiratory distress syndrome (ARDS) on V-V ECMO with an ultrasound dilution technique.\n\nECMO blood flow will be optimized by reducing ECMO blood flow in accordance with the measured Rf as long as systemic oxygenation is not compromised.",[28,73],"2024-12-28",{"date":393,"type":43},"2024-12-31",{"date":395,"type":43},"2020-11-20",{"date":397,"type":21},"2026-10-31",{"name":399,"class":50},"Charite University, Berlin, Germany",{"id":401,"slug":402,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":17,"minAge":408,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":22,"phases":411,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":51},"100479802","phase-4-revascularization-strategy-of-multivessel-disease-for-patients-with-acute-myocardial-infarction-complicated-by-cardiogenic-shock-undergoing-veno-arterial-extracorporeal-membrane-oxygenator-100479802","NCT05527717","Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator","REvaSCUlarization StratEgy of Multivessel Coronary Artery Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic SHOCK Undergoing Veno-arterial Extracorporeal Membrane Oxygenator: Randomized-Controlled Trial (RESCUE-SHOCK)","RESCUE-SHOCK","Inclusion Criteria:\n\n* Subject must be at least 19 years of age\n* Patients presented with AMI (ST-segment elevation MI \\[STEMI\\] or non-ST-segment elevation MI \\[NSTEMI\\]) complicated by CS (SCAI Shock classification C, D or E) who requiring VA-ECMO.\n* Target lesions amenable for planned primary PCI by operators' decision\n* Patients with multi-vessel disease\n\nExclusion Criteria:\n\n* Other causes of shock (hypovolemia, sepsis, obstructive shock).\n* Shock due to mechanical complication to MI (rupture of papillary muscle, the ventricular septum, or free wall).\n* Unwitnessed out of hospital cardiac arrest with persistent Glasgow coma scale \\\u003C8 after the return of spontaneous circulation.\n* Patients with single-vessel disease (Patients with single-vessel disease will be enrolled in the RESCUE-SHOCK registry)\n* Onset of shock \\>24 hours.\n* Known heparin intolerance.\n* Other severe concomitant disease with limited life expectancy \\\u003C 6 months\n* Pregnancy or breast feeding\n* Do not resuscitate wish","19 Years",{"count":410,"type":21},560,[412],"PHASE4","This study is a prospective, open-label, two-arm, randomized multicenter trial to identify whether immediate multi-vessel PCI would be better in clinical outcomes compared with culprit lesion-only PCI for AMI and multi-vessel disease with an advanced form of CS patients who require veno-arterial extracorporeal membrane oxygenator (VA-ECMO).",[27,415,416,28],"Acute Myocardial Infarction","Multi Vessel Coronary Artery Disease","2024-11-04",{"date":419,"type":43},"2024-11-06",{"date":421,"type":43},"2022-11-16",{"date":423,"type":21},"2028-12-31",{"name":425,"class":50},"Samsung Medical Center",{"id":427,"slug":428,"hasResults":11,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":434,"enrollmentInfo":435,"targetDuration":4,"studyType":22,"phases":437,"briefSummary":438,"conditions":439,"keywords":444,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":456},"100482474","trial-of-venovenous-ecmo-to-de-sedate-extubate-and-mobilise-in-hypoxic-respiratory-failure-100482474","NCT05562505","Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure","A Randomised Controlled Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure","REDEEM","Inclusion Criteria:\n\n1. Patients ≥18 to 65 years old\n2. Acute hypoxemic respiratory failure characterised by new or worsening respiratory symptoms developing within 2 weeks prior to the onset of need for oxygen or respiratory support\n3. Mechanical ventilation of \\\u003C7 days\n4. Moderate to severe respiratory failure, as demonstrated by two P:F ratios \\\u003C150mmHg at least 6 hours apart. Arterial Blood Gases (ABG) with P:F ratio \\> 150mmHg are permitted between the two trial inclusion ABGs.\n5. Trial of proning (unless contraindicated)\n\nExclusion Criteria:\n\n1. The patient will be extubated today or tomorrow (i.e. will not remain intubated and ventilated the day after tomorrow)\n2. Cardiogenic cause of respiratory failure\n3. Chronic hypercapnic respiratory failure defined as PaCO2 \\> 60 mmHg in the outpatient setting\n4. Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for CPAP\u002FBIPAP used solely for sleep disordered breathing\n5. Confirmed diffuse alveolar haemorrhage from vasculitis\n6. Neurologic conditions, i.e. undergoing treatment for intracranial hypertension\n7. Currently receiving any form of ECMO (e.g., venovenous, venoarterial, or hybrid configuration)\n8. Patient needing immediate VV ECMO (as per EOLIA criteria)\n9. The patient is moribund and deemed unlikely to survive past 24 hours (as determined by the clinical team)\n10. The patient is being transitioned to palliative care\n11. Contraindications to anticoagulation (e.g., active GI bleeding, bleeding predisposition, severe trauma)\n12. Previous hypersensitivity\u002Fanaphylactic reaction to heparin or heparin-induced thrombocytopenia\n13. Participation or Consent is declined, OR\n14. Unable to identify or Contact surrogate decision maker.","65 Years",{"count":436,"type":21},140,[63],"To determine whether a strategy of adding venovenous ECMO to mechanical ventilation, as compared to mechanical ventilation alone, increases the number of intensive care free days at day 60, in patients with moderate to severe acute hypoxic respiratory failure.",[440,441,442,443,74,28],"Mechanical Ventilation Complication","Hypoxemia","Acute Respiratory Distress Syndrome Due to COVID-19","COVID-19 Respiratory Infection",[119,33,28,445,446],"Mechanical Ventilation","Early ECMO","2024-08-06",{"date":449,"type":43},"2024-08-09",{"date":451,"type":43},"2022-11-28",{"date":453,"type":21},"2027-01-31",{"name":455,"class":50},"Australian and New Zealand Intensive Care Research Centre",7,{"id":458,"slug":459,"hasResults":11,"nctId":460,"briefTitle":461,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":463,"enrollmentInfo":464,"targetDuration":4,"studyType":22,"phases":466,"briefSummary":468,"conditions":469,"keywords":470,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":51},"100482704","phase-2-the-effects-of-ecmo-on-the-pharmacokinetics-of-hydromorphone-100482704","NCT05565495","The Effects of ECMO on the Pharmacokinetics of Hydromorphone","Inclusion Criteria:\n\n* Between the ages of 18 and 80;\n* Using hydromorphone for pain relief;\n* Using ECMO for more than 96h\n\nExclusion Criteria:\n\n* Allergic to hydromorphone;\n* Use of CRRT during ECMO;\n* Liver function Child-Pugh B, C grade;\n* Pregnancy;\n* Intestinal obstruction;\n* Refused to sign the informed consent.","80 Years",{"count":465,"type":21},26,[467],"PHASE2","The purpose of this study was to establish a population pharmacokinetic (PPK) model of hydromorphone in patients under ECMO, and to recommend a dosing regimen when the target effective concentration was reached.",[28],[28,471,472],"Pharmacokinetics","Hydromorphone","2024-08-05",{"date":447,"type":43},{"date":476,"type":43},"2022-01-01",{"date":478,"type":21},"2024-09-01",{"name":480,"class":50},"Xiaobo Yang, MD",{"id":482,"slug":483,"hasResults":11,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":11,"sex":17,"minAge":489,"maxAge":18,"enrollmentInfo":490,"targetDuration":4,"studyType":22,"phases":491,"briefSummary":492,"conditions":493,"keywords":495,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":505,"locationsCount":507},"100544492","prone-position-during-ecmo-in-pediatric-patients-with-severe-ards-100544492","NCT06369584","Prone Position During ECMO in Pediatric Patients With Severe ARDS","Efficiency and Safety of Prone Position During Extracorporeal Membrane Oxygenation in Pediatric Patients With Severe Acute Respiratory Distress Syndrome: A Multi-center Randomized Study","PEPAD","Inclusion Criteria:\n\n* Severe PARDS and meets the criteria for ECMO support, has received ECMO support for less than 48 hours.\n* Informed consent obtained from the child's direct\u002Flegal guardian\n\nExclusion Criteria:\n\n1. Age \\\u003C 1 month or \\> 18 years old.\n2. ECMO initiated for more than 48 hours.\n3. Children who have undergone cardiopulmonary resuscitation (CPR) for more than 10 minutes before ECMO initiation without restoration of spontaneous circulation, or children undergoing extracorporeal cardiopulmonary resuscitation (ECPR).\n4. Presence of irreversible brain injury or intracranial hypertension.\n5. Children with irreversible lung disease awaiting lung transplantation.\n6. Children with abdominal trauma or postoperative acute respiratory distress syndrome (ARDS).\n7. Children in whom percutaneous cannulation cannot be performed due to unstable hemodynamics within the first 48 hours after ECMO support initiation.\n8. Other contraindications for performing percutaneous cannulation.\n9. Liver failure.\n10. Burn area \\>20% body surface area (BSA).","1 Month",{"count":456,"type":21},[63],"In 2023, the second Pediatric Acute Lung Injury Consensus Conference (PALICC-2) updated the diagnostic and management guidelines for Pediatric Acute Respiratory Distress Syndrome (PARDS). The guidelines do not provide sufficient evidence-based recommendations on whether prone positioning ventilation is necessary for severe PARDS patients. However, the effectiveness of Extracorporeal Membrane Oxygenation (ECMO) in treating severe PARDS has been fluctuating around 70% according to recent data from Extracorporeal Life Support Organization (ELSO).\n\nIn 2018, the Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE) study group conducted a retrospective analysis and concluded that ECMO does not significantly improve survival rates for severe PARDS. However, this retrospective study mainly focused on data from North America, with significant variations in annual ECMO support cases among different centers, which may introduce bias. With advancements in ECMO technology and materials, ECMO has become safer and easier to operate. In recent years, pediatric ECMO support technology has rapidly grown in mainland China and is increasingly being widely used domestically to rescue more children promptly.\n\nECMO can also serve as a salvage measure for severely ARDS children who have failed conventional mechanical ventilation treatment. When optimizing ventilator parameters (titrating positive end expiratory pressure (PEEP) levels, neuromuscular blockers, prone positioning), strict fluid management alone cannot maintain satisfactory oxygenation (P\u002FF\\\u003C80mmHg or Oxygen Index (OI) \\>40 for over 4 hours or OI \\>20 for over 24 hours), initiating ECMO can achieve lung-protective ventilation strategies with ultra-low tidal volumes to minimize ventilator-associated lung injury.",[494,28],"Pediatric Acute Respiratory Distress Syndrome",[496,497,498],"Extracorporeal Membrane oxygenation","pediatric acute respiratory distress syndrome","prone position ventilation","2024-06-07",{"date":501,"type":43},"2024-06-10",{"date":503,"type":43},"2024-05-09",{"date":243,"type":21},{"name":506,"class":50},"Seventh Medical Center of PLA General Hospital",8,{"id":509,"slug":510,"hasResults":11,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":518,"conditions":519,"keywords":520,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":51},"100546886","estimation-of-outcome-and-quality-of-life-in-ecmo-patients-100546886","NCT06400797","Estimation of Outcome and Quality of Life in ECMO Patients","ESTimation of Outcome by Health-Care PRoviders Compared With TruE Outcome in Patients Undergoing Veno-arteriaL and Veno-venous ExtracorporeaL MembrAne Oxygenation","ESTRELLA","Inclusion Criteria:\n\n* age ≥ 18 years\n* start of ECMO therapy ≤24h\n* written informed consent from patient or health-care proxy\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* Language barrier (communication in German\u002Flocal language or English not possible).\n* no ECMO therapy or ECMO therapy longer than 24h\n* no written consent",{"count":517,"type":21},1000,"The availability as well as the use of extracorporeal membrane oxygenation (ECMO) systems for severe acute respiratory or cardiocirculatory failure is steadily increasing. The decision to initiate ECMO therapy is predominantly made in emergency situations, for which the focus is on acute survival. The decisions if a patient will profit from ECMO therapy are mainly made from clinical experience and educated guess by the attending team. However, it is unknown how useful these clinical predictions are. Therefore, this observational study will compare estimated and real outcome of ECMO patients.",[28],[33,521,522],"health related quality of life","Outcome estimation","2024-05-02",{"date":525,"type":43},"2024-05-06",{"date":527,"type":43},"2024-01-01",{"date":529,"type":21},"2029-01-01",{"name":531,"class":50},"Heinrich-Heine University, Duesseldorf"]